However, recent advances in the modulation of immune responses against cancer have changed paradigms, and with the first regulatory approval of a novel immunotherapeutic agent targeting an immune checkpoint, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), ipilimumab, the future of cancer care was changed forever. Here, CTLA4 is linked to cancer.